ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer
KEYNOTE-355 Mixed On PFS; Still Waiting On OS
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
You may also be interested in...
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
Roche has resolved the issues raised by the health technology assessment body over what is the first immunotherapy approved for treating this aggressive and difficult-to-treat form of breast cancer.
The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda.